Source link : https://newshealth.biz/health-news/alzheimers-med-continues-to-deliver-benefit-at-3-years/
Data from the TRAILBLAZER-ALZ 2 long-term extension (LTE) study demonstrated that donanemab (Kisunla, Eli Lilly and Company) continues to deliver meaningful benefits that increase over 3 years, especially when started early, with a manageable safety profile. “There was a 27% reduced risk of progression if you were started initially in the trial versus delayed in […]
The post Alzheimer’s Med Continues to Deliver Benefit at 3 Years first appeared on News Health.
—-
Author : News Health
Publish date : 2025-08-21 11:20:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8